Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FoldRx Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

When a protein faiils to fold properly, its function is lost and disease may follow. FoldRx Pharmaceuticals hopes to become the first company to develop agents that target misfolded proteins to stop the many diseases they cause.

You may also be interested in...



AC Immune SA

Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.

AC Immune SA

Swiss-based AC Immune SA is using both an immunological and a small molecule approach to tackling Alzheimer's disease. It hopes that both techniques may lead to compounds that may, by re-balancing the equilibrium between mutant and harmless forms of the protein amyloid beta, halt and perhaps even reverse the progression of the disease.

Protein Structure/Function Determination

After 20 years and the efforts of thousands of researchers working on the problem structures have only been revealed for about 20,000 proteins out of 500,000 known protein sequences. When combined with the latest experimental and computational techniques, sequence and structural information provide some useful guidelines. Pharmaceutical companies are using it to sift from massive amounts of sequence information a more manageable number of biologically relevant targets; the undertaking is now known as structural genomics. Today this field is a hotbed of activity for new companies that offer improved X-ray crystallography techniques, nuclear magnetic resonance spectroscopy, annotated protein databases, computational algorithms, and combinations of all of the above.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel